

## **DIMERIX RECEIVES INITIAL UPFRONT PAYMENT FROM AMICUS**

- Dimerix has received the upfront payment of US\$30 million (~AU\$48 million<sup>1</sup>) from Amicus Therapeutics
- Dimerix remains eligible for further potential development milestones of up to US\$560 million (~AU\$892 million<sup>1</sup>) for success-based milestone payments, in addition to tiered royalties on DMX 200 net US sales
- Amicus was the fourth license deal executed for DMX-200<sup>2</sup> following the license deals with Advanz Pharma (announced October 2023)<sup>3</sup>, Taiba (announced May 2024)<sup>4</sup>, and Fuso (announced 7 January 2025)<sup>5</sup>
  - Collectively the license deals provide up to ~AU\$1.4 billion<sup>6</sup> in total upfront payments and potential milestone payments, plus royalties on net sales
- Dimerix retains all rights to DMX-200 in all territories other than those covered by the Amicus<sup>2</sup>, Advanz Pharma<sup>3</sup>, Taiba<sup>4</sup> and FUSO<sup>5</sup>, license agreements
- Dimerix continues to focus on ACTION3 Phase 3 clinical trial delivery and licensing opportunities with potential partners in territories not already licensed

MELBOURNE, Australia, 6 May 2025: Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical asset in kidney disease, today announced that it has received the initial payment of US\$30 million (AU\$48 million<sup>1</sup>) in line with the recently announced license agreement with Amicus Therapeutics.<sup>2</sup> Under the agreement, Amicus has been granted exclusive rights to commercialise DMX-200 for FSGS in the United States.

Dimerix now has four high quality partners across multiple territories, providing strong support for Dimerix in advancing and commercialising DMX-200 as a potential new treatment for FSGS. Collectively across all licences, Dimerix may become eligible for up to ~AU\$1.4 billion<sup>6</sup> in total upfront payments and potential milestone payments, plus royalties on net sales.

Under the Amicus agreement, Dimerix may become eligible to receive potential success-based development and regulatory milestone payments of up to US\$75 million (~AU\$119 million<sup>1</sup>) until FDA approval of DMX-200 in FSGS, US\$35 million (~AU\$56 million<sup>1</sup>) on first sale, commercial sales milestone payments of up to US\$410 million (AU\$653 million<sup>1</sup>), and tiered royalties from the low-teens to low-twenties percentages of DMX 200 net sales in the U.S. In addition, Dimerix is eligible to receive up to US\$40 million (~AU\$64 million<sup>1</sup>) in milestone payments for potential future indications.

Dimerix continues to focus on licensing opportunities with potential partners in territories other than those covered by the Amicus<sup>2</sup>, Advanz Pharma<sup>3</sup>, Taiba<sup>4</sup> and FUSO<sup>5</sup> license agreements.

About  **ACTION3** FSGS Phase 3 Study  
FSGS CLINICAL STUDY

The Phase 3 study, which is titled “Angiotensin II Type 1 Receptor (AT1R) & Chemokine Receptor 2 (CCR2) Targets for Inflammatory Nephrosis”, or ACTION3 for short, is a pivotal (Phase 3), multi-centre, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with FSGS who are receiving a stable dose of an angiotensin II receptor blocker (ARB). Once the ARB dose is stable, patients will be randomized to receive either DMX-200 (120 mg capsule twice daily) or placebo.

The single Phase 3 trial in FSGS patients has two interim analysis points built in that are designed to capture evidence of proteinuria and kidney function (eGFR slope) during the trial, aimed at generating sufficient evidence to support marketing approval. Further information about the study can be found on ClinicalTrials.gov (Study Identifier: NCT05183646) or Australian New Zealand Clinical Trials Registry (ANZCTR) (Study Identifier ACTRN12622000066785).

For further information, please visit our website at [www.dimerix.com](http://www.dimerix.com) or contact:

Dr Nina Webster  
Dimerix Limited  
Chief Executive Officer & Managing Director  
Tel: +61 1300 813 321  
E: [investor@dimerix.com](mailto:investor@dimerix.com)

Rudi Michelson  
Monsoon Communications  
Tel: +61 3 9620 3333  
Mob: +61 (0)411 402 737  
E: [rudim@monsoon.com.au](mailto:rudim@monsoon.com.au)

Follow us on [LinkedIn](#) and [Twitter](#)

*Authorised for lodgement by the Board of the Company*

—END—

### **About Dimerix Limited**

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company working to improve the lives of patients with inflammatory diseases, including kidney diseases. Dimerix is currently focused on developing its proprietary Phase 3 product candidate DMX-200, for Focal Segmental Glomerulosclerosis (FSGS) kidney disease, and is also developing DMX-700 for respiratory disease. DMX-200 and DMX-700 were both identified using Dimerix’ proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. For more information, please visit the company’s website at [www.dimerix.com](http://www.dimerix.com) and follow on [X](#) and [LinkedIn](#).

## About DMX-200

DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. DMX-200 is protected by granted patents in various territories until 2032, with patent applications submitted globally that may extend patent protection to 2042, in addition to Orphan Drug Designation granted by the FDA in the United States.

## About FSGS

FSGS is a rare, serious kidney disorder characterized by progressive scarring (sclerosis) in parts of the glomeruli—the kidney’s filtering units. This scarring leads to proteinuria, progressive loss of kidney function, and often end-stage renal disease. FSGS is increasingly understood to have an inflammatory component, with monocyte and macrophage activation contributing to glomerular injury. In the United States, more than 40,000 people are estimated to be living with FSGS, including both adults and children.<sup>7</sup> There are no therapies specifically approved for FSGS in the U.S., and management relies on non-specific immunosuppressive and supportive therapies. In patients with progressive or treatment-resistant FSGS, the average time from diagnosis to end-stage kidney disease can be as short as five years. Even among those who undergo kidney transplantation, disease recurrence occurs in up to 60% of cases,<sup>8</sup> underscoring the urgent need for new, disease-modifying treatments.

## Dimerix Forward Looking Statement

This release includes forward-looking statements that are subject to risks and uncertainties. Although management believes that the expectations reflected in the forward looking statements are reasonable at this time, Dimerix can give no assurance that these expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements. Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, results of clinical trials, contractual risks, risks associated with patent protection, future capital needs or other general risks or factors, along with those factors outlined in the most recent Dimerix Limited Annual Report.

## References

- 
- 1 *Based on 30 day Wall Street Journal average exchange rate of 1 USD = 1.5924 AUD from 28 March - 28 April 2025*
  - 2 *ASX release 01 May 2025*
  - 3 *ASX release 5 October 2023*
  - 4 *ASX release 27 May 2024*
  - 5 *ASX release 7 January 2025*
  - 6 *Based on XE exchange rates & further terms outlined in ASX Announcements on 5 October 2023, 27 May 2024, 07 January 2025, and 01 May 2025;*
  - 7 *Nephcure FSGS Facts (<https://nephcure.org/>)*
  - 8 *Front. Immunol., (July 2019) | <https://doi.org/10.3389/fimmu.2019.01669>*